U.S. markets open in 15 minutes

  • S&P Futures

    4,378.00
    +16.75 (+0.38%)
     

  • Dow Futures

    34,869.00
    +93.00 (+0.27%)
     

  • Nasdaq Futures

    14,963.25
    +98.25 (+0.66%)
     

  • Russell 2000 Futures

    2,250.60
    +16.40 (+0.73%)
     

  • Crude Oil

    75.14
    -0.11 (-0.15%)
     

  • Gold

    1,829.00
    +19.10 (+1.06%)
     

  • Silver

    26.50
    +0.36 (+1.38%)
     

  • EUR/USD

    1.1823
    +0.0035 (+0.30%)
     

  • 10-Yr Bond

    1.3710
    -0.0440 (-3.11%)
     

  • Vix

    16.23
    +0.06 (+0.37%)
     

  • GBP/USD

    1.3883
    +0.0072 (+0.52%)
     

  • USD/JPY

    110.1120
    -0.4840 (-0.44%)
     

  • BTC-USD

    32,506.41
    +48.70 (+0.15%)
     

  • CMC Crypto 200

    788.47
    -20.26 (-2.50%)
     

  • FTSE 100

    7,096.67
    -28.05 (-0.39%)
     

  • Nikkei 225

    28,608.49
    -109.75 (-0.38%)
     

Dr. Alan Ettinger, DPM Endorses CHI Footwear

·3 min read

Iconic haircare brand CHI expands focus from head to toe, working with a top doctor of podiatric medicine to showcase the foot health benefits of CHI's Graphene Sneakers

HOUSTON, July 14, 2021 /PRNewswire/ -- Farouk Shami, Chairman of Farouk Systems Inc., announces a new endorsement with Dr. Alan Ettinger, DPM. As a Board-Certified Member of American Podiatric Medicine, Dr. Ettinger will be CHI Footwear's top medical resource, exploring the numerous foot health benefits offered by CHI's Graphene Sneaker Collection.

CHI Footwear Graphene Sneaker Collection
CHI Footwear Graphene Sneaker Collection

"When we think about our health, we often consider the foods we eat, the water we drink and the exercise we do for our bodies. But do we ever stop to think about foot health and how this impacts our overall well-being?" explains Dr. Alan Ettinger. "This is why preventative footwear is more important today than ever. The right shoes are key in fighting bacterial and viral infections, fungal growth, possible wounds or further complications."

As a result, a first line of defense to preventing foot conditions like this is through the material in the shoes we wear daily (leather vs man-made). Through intensive research, testing and a variety of prototypes, CHI Footwear developed a next-gen sneaker design that protects consumers from a host of foot problems including bacteria, poor circulation, sweat, odor and foot fatigue – all thanks to the line's Graphene Technology. Considered to be the strongest material in the world, graphene is a razor-thin honeycomb sheet of carbon atoms that is 200 times stronger than steel, but extremely lightweight.

In particular, CHI Footwear's Graphene Sneakers and Inserts:

  • Help to kill germs by breaking down the cellular walls of bacteria, fungus, yeast and certain types of viruses.

  • Prevent odors

  • Provide relief for plantar fasciitis - one of the most common causes of heel pain

  • Provide stability and balance

  • Regulate body temperature for optimal comfort and support

  • Reduce muscle fatigue

  • Encourage you to stand and walk properly which may correct posture over time

  • May provide a heathy option for diabetic footwear

  • Feature insoles with acupoints to help massage the foot while walking, providing energy and good circulation while fighting fatigue

Available in women's and men's sizes, this 15-piece sneaker collection implements this technology to ensure consumers do not need to compromise on comfort or style. The Collection comes in a variety of attractive color combinations with many of the designs inspired by the Eye of Horus, an ancient Egyptian symbol of protection, good health and energy.

Price: $269 each from https://chifootwear.com/our-materials/ or https://chi.com/chi-footwear/#shop (chi.com is connected to rewardStyle, Skimlinks and Viglink)

Style, Comfort, and Technology all in one.

For more information, please visit www.chifootwear.com
https://www.youtube.com/watch?v=omQWZo0L-fE
https://www.youtube.com/watch?v=vocoMgPwa8o
Get social with us @chifootwear

Contacts: Janice McCafferty
Jessica McCafferty
Janice McCafferty Communications
773-736-9034
314383@email4pr.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-alan-ettinger-dpm-endorses-chi-footwear-301333384.html

SOURCE Farouk Systems Inc.

Recommended Stories

  • 5 Stocks to Own for the Surge in Coronavirus Variants

    Although the pandemic has mostly faded from the front pages, mutations of the SARS-CoV-2 virus are increasing the odds that COVID will make a resurgence this winter. Add in many Americans' hesitancy over vaccines, and it appears the companies providing testing, treatments, and vaccine boosters could remain a part of our lives longer than it seemed only a few months ago. Revenue rose 1,200% on the back of a 74-fold increase in testing volume.

  • Coronavirus: 'We have a tale of two pandemics' in America

    The growing number of COVID cases in the U.S. indicates a major divide between the vaccinated population and those who choose to remain unvaccinated.

  • Top FDA Staffers Defend Approval of Biogen’s Alzheimer’s Drug in Medical Journal

    The officials, writing in a medical journal, say patient representatives told them they were willing to accept uncertainty about the drug’s clinical benefit.

  • 3 Things About Invitae That Smart Investors Should Know

    Invitae (NYSE: NVTA) is on a mission "to bring comprehensive genetic information to mainstream medicine to improve healthcare for billions." In medical terms, Invitae can help the roughly one in six people who have a medical condition with an underlying genetic component. In financial terms, Invitae has the potential to generate several hundred dollars annually from more than 2 billion people -- a staggering market opportunity of $4 trillion.

  • COVID cases jump in 47 states as Delta variant spreads

    The Delta variant is fueling a spike in COVID cases, mostly among people who are not vaccinated. Omar Villafranca has more.

  • The CDC and FDA Just Issued a Warning About a New Delayed Vaccine Side Effect

    The Johnson&Johnson COVID vaccine has faced its fair share of issues, from the potential of causing blood clots to its lower efficacy rate. Now, officials are saying the one-dose regimen could also have another new concerning side effect. On Monday, July 12, the Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) released a new warning about a potential reaction to the Johnson&Johnson vaccine that's cropped up among a certain demographic, weeks after they

  • Investors Eyeing NovoCure’s Ovarian Cancer Treatment Trials

    The global oncology company NovoCure Ltd (NASDAQ: NVCR), which is focused on the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields), has been in the headlines lately. The company is striving to widen the survival of patients who have some of the most aggressive forms of cancer. Notably, the company is working on, or has completed, clinical trials related to TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, live

  • Is BMY Stock A Buy As Shares Surge On Promising Cancer Treatment Data?

    Is BMY stock a buy after Bristol Myers Squibb said a cancer drug called Breyanzi outperformed the standard treatment in patients with a form of lymphoma?

  • At 48, Heidi Klum Looks So Sculpted While Sunbathing Nude In New Instagram Photo

    Her hubby snapped the "HOT" pic.

  • Why the CDC and FDA Just Slapped Down Pfizer and Moderna

    Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.

  • ‘I am 30 and have no reason to get vaccinated.’ Getting COVID-19 shots in the arms of young adults a challenge for public health experts.

    CHICAGO — Sally Vala says she has no desire to get the COVID-19 vaccine, in part because she’s relatively young and has no major health problems. “I am 30 and have no reason to get vaccinated,” said the west suburban Downers Grove woman. “I’m healthy, exercise and have been fine since this whole thing started. No plans on getting the vaccine.” As public health officials race to vaccinate ...

  • Are the COVID booster shots good science—or just greed?

    With rich countries already hoarding vaccines, the booster debate has moral and ethical implications.

  • US Medicare Starts Coverage Policy Review For Biogen's Aduhelm

    The U.S. government started a review process for national Medicare coverage of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm. The Centers for Medicare & Medicaid Services expects to give a proposed decision within six months and a final decision within nine months. Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged 65 and older. The review will include an analysis of published clinical studies and medica

  • Biogen Inks Deal with InnoCare on Orelabrutinib

    Biogen (BIIB) recently inked a license and partnership agreement with InnoCare Pharma Limited. Biogen will gain exclusive rights to Orelabrutinib for the worldwide treatment of multiple sclerosis (MS) and few other autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan). InnoCare will keep its exclusive rights to use Orelabrutinib to treat cancer and other autoimmune diseases in China. Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) that is admini

  • After FDA Warning, EMA Reviewing J&J COVID-19 Jab For Rare Nerve Disorder: Reuters

    On Tuesday, the European Medicines Agency (EMA) said it was analyzing data on rare cases of a nerve disorder reported among recipients of Johnson & Johnson's (NYSE: JNJ) COVID-19 shot, Reuters reported. The FDA issued a warning that there are data "connecting the shot to an increased risk" of Guillain-Barré syndrome, a rare condition where the body's immune system attacks its nerves. The EMA's safety committee (PRAC) is analyzing data provided by the company on cases of Guillain-Barre syndrome (

  • Catt Sadler Is Sick with COVID After Getting Fully Vaccinated: 'Delta Is Relentless'

    The entertainment reporter said she was caring for an unvaccinated person with COVID-19 and contracted the virus

  • Infections Surge in Asia; Optional Masks in U.K.: Virus Update

    (Bloomberg) -- U.K. Prime Minister Boris Johnson is facing a backlash from businesses and officials across the country over his decision to make masks optional starting Monday. Sydney extended its lockdown for a further two weeks as Australia’s most populous city battles an outbreak of the delta strain, with health authorities increasingly concerned after infections spread to Melbourne.Indonesia’s daily cases surpassed India’s, marking a new virus epicenter in Asia as delta drives up infections.

  • Medicare Is Already Deciding Whether to Cover Biogen’s Alzheimer’s Drug

    The agency responsible for managing the Medicare program said late last week it had begun a process to set a national policy on how to cover Aduhelm.

  • Volunteer ambulance drivers help take the strain on Indonesia's COVID frontline

    As Indonesia's health service struggles to cope with soaring coronavirus infections, volunteer ambulance drivers like Sunaryo have been working flat out to bring infected patients to and from hospitals. "I definitely feel scared (about being infected)... But this is for humanity and I'm doing this from my heart," said Sunaryo. Working alongside government ambulances, the volunteers are playing a vital role in supporting the creaking public healthcare service on Java, Indonesia's most densely populated island.

  • Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas

    (Bloomberg) -- Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resign